VERU
Veru Inc
NASDAQ · Pharmaceuticals
$2.34
+0.10 (+4.46%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.40M | 6.59M | 7.88M |
| Net Income | 1.82M | 1.64M | 1.71M |
| EPS | — | — | — |
| Profit Margin | 24.6% | 24.9% | 21.7% |
| Rev Growth | -0.5% | +19.2% | -4.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 6.45M | 6.76M | 7.86M |
| Total Equity | 16.85M | 15.00M | 16.14M |
| D/E Ratio | 0.38 | 0.45 | 0.49 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 3.84M | 3.19M | 3.50M |
| Free Cash Flow | 1.31M | 1.30M | 1.17M |